Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridostigmine for HIV-associated Autonomic Neuropathy
NCT02850276Phase 1Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Nov 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pyridostigmine in autonomic neuropathy (AN), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: Change in Breath Test at 8 weeks and Number of Participants With Reduction in Small Intestinal Bacterial Overgrowth (SIBO) at 8 weeks. Started Nov 2015; status: completed.
02
Drugs
pyridostigmine
03
Conditions
autonomic neuropathy (AN)
Beyond the preview
Go deeper on NCT02850276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02850276.